Corcept Therapeutics(NASDAQ) CORT

Corcept Therapeutics Incorporated makes medicine for people with serious hormone disorders. Their main treatments help patients manage excess cortisol in their bodies. These drugs treat conditions like Cushing's syndrome and certain cancers.

What Does Corcept Sell?

• Hypercortisolism Products: Korlym and its authorized generic version treat adult patients with endogenous Cushing's syndrome, a condition caused by excessive cortisol hormone levels; generated $208.6 million in net product revenue for the three-month period ended June 30, 2026.
• Lifyorli: Medication used with chemotherapy to treat patients with platinum-resistant ovarian cancer, which means the cancer does not respond to standard treatments; generated $47.6 million in net product revenue during the three-month period ended June 30, 2026.
• Selective Modulators: Pipeline of over 1,000 proprietary compounds designed to regulate cortisol activity while avoiding side effects like low potassium or endometrial thickening.

Recent Steps and Future Plans

• Launched Lifyorli in the United States in April 2026 following FDA approval for the treatment of platinum-resistant ovarian cancer.
• Resubmitted a New Drug Application for relacorilant to the FDA on June 17, 2026, to seek approval for treating Cushing's syndrome.
• Introduced an authorized generic version of Korlym in June 2024 to expand its commercial hypercortisolism treatment options.
• Initiated the Phase 2 TRIDENT trial in Dec. 2025 to evaluate relacorilant as a potential treatment for patients with pancreatic cancer.

A Focus on Targeted Modulation

Corcept reaches patients through exclusive pharmacy vendors and medical science liaisons rather than using traditional wholesale drug channels. Its platform develops selective modulators to regulate cortisol without causing the side effects associated with older receptor-blocking drugs.

Performance by the Numbers

• Net product revenue reached $421.1 million for the six-month period ended June 30, 2026, compared to $351.6 million for the same period in 2025.
• Selling, general, and administrative expense was $156.9 million for the three-month period ended June 30, 2026, up from $103.9 million year over year.
• Cash, cash equivalents, and marketable securities totaled $544.6 million as of June 30, 2026.
• Market capitalization was $10.0 billion as of late 2026.

The Path Forward

Corcept has transitioned from a single-product company focused on Cushing's syndrome to a commercial-stage oncology and endocrinology business. Its expanding pipeline of selective modulators targets diverse conditions ranging from liver disease to neurological illnesses.